• KOL
    • Atopic Dermatitis
    • Elaine C Siegfried
    • Elaine C Siegfried: Influence Statistics

      Elaine C Siegfried

      Elaine C Siegfried

      Show email address

      Departments of Pediatrics and Dermatology, Saint Louis University School of Medicine, St. Louis, Missouri, USA | Division of Dermatology, Department of Pediatrics, Cardinal ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Elaine C Siegfried:Expert Impact

      Concepts for whichElaine C Siegfriedhas direct influence:Atopic dermatitis,Pediatric patients,Eczema herpeticum,Pyoderma gangrenosum,Molluscum contagiosum,Systemic agents,Anatomical regions,Severe atopic dermatitis.

      Elaine C Siegfried:KOL impact

      Concepts related to the work of other authors for whichfor which Elaine C Siegfried has influence:Atopic dermatitis,Infantile hemangiomas,Acne vulgaris,Netherton syndrome,Oral propranolol,Pediatric psoriasis,Alopecia areata.

      KOL Resume for Elaine C Siegfried

      Year
      2022

      Departments of Pediatrics and Dermatology, Saint Louis University School of Medicine, St. Louis, Missouri, USA

      2021

      Cardinal Glennon Children’s Hospital, St. Louis, Missouri, USA

      Department of Pediatrics and Dermatology, St Louis University, St Louis, Missouri

      2020

      Saint Louis University, Saint Louis, Missouri.

      Department of Pediatrics, St Louis University School of Medicine, St Louis, Missouri

      2019

      Saint Louis University, Saint Louis, Missouri

      2018

      Saint Louis University and Cardinal Glennon Children’s Hospital, St. Louis, MO, USA

      Cardinal Glennon Children's Hospital, St. Louis, MO

      2017

      Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri

      Cardinal Glennon Children's Medical Center St. Louis MO USA

      2016

      Department of Pediatrics and Dermatology, Saint Louis University, Cardinal Glennon Children's Hospital, St Louis, Missouri

      Saint Louis University, Cardinal Glennon Children’s Hospital, 1465 South Grand Avenue, St Louis, MO 63104 USA

      2015

      Saint Louis University School of Medicine St. Louis Missouri

      2014

      Saint Louis University Cardinal Glennon Children's Hospital Department of Pediatrics St. Louis Missouri

      2013

      Department of Pediatrics, Saint Louis University School of Medicine, Cardinal Glennon Children's Medical Center, St Louis, Missouri

      Division of Dermatology, Cardinal Glennon Children's Medical Center and Saint Louis University School of Medicine, St. Louis, MO

      2012

      Departments of Dermatology and Pediatrics, St Louis University School of Medicine, St Louis, Missouri (Dr Siegfried). Dr Glenn was a medical student at the St Louis University School of Medicine and is now with the Department of Pediatrics at Children's Hospital and Research Center Oakland, Oakland, California.

      2011

      Department of Pediatrics and Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri

      2010

      Saint Louis, Missouri
e‐mail:

      2009

      Saint Louis University, Department of Pediatrics and Dermatology, St. Louis, Missouri

      2008

      Professor of Pediatrics and Medicine (Dermatology), University of California, San Diego School of Medicine

      Cardinal Glennon Children's Hospital and Saint Louis University, St. Louis (E.C.S.)

      Chief, Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, San Diego, California, USA

      Central Dermatology, St. Louis, Missouri

      2007

      Department of Dermatology, St Louis University School of Medicine, St Louis

      2006

      St Louis University School of Medicine and Kids Dermatology, St Louis, MO 63141, USA.

      Department of Dermatology, and Kids Dermatology,

      2005

      Professor of Pediatrics and Obstetrics and Gynecology, University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

      Kids Dermatology, 621 S. New Ballas Road, St. Louis, MO 63141, USA.

      Head, Division of Neonatology, University of Washington, Children's Hospital and Regional Medical Center, Seattle, Washington

      2004

      Department of Dermatology, St Louis University School of Medicine, St Louis, Missouri, USA

      2003

      From the Department of Dermatology, University of Cincinnati, Cincinnati, Ohio; the Department of Dermatology, Duke University, Durham, North Carolina; the Department of Dermatology, University of Missouri, and the Department of Pediatrics and Dermatology, St Louis University, St Louis, Missouri; and the Departments of Pathology and Dermatology, University of California, San Francisco, San Francisco, California, USA

      2002

      Department of Dermatology, Saint Louis University School of Medicine, St. Louis, Missouri

      2001

      Department of Pediatrics, Saint Louis University School of Medicine, St Louis, Missouri, U.S.A.

      2000

      Departments of *Dermatology and Pediatrics, Saint Louis University Medical Center, Saint Louis, Missouri, USA

      1999

      From the Departments of Dermatology,a Pediatrics,b and Internal Medicine,c Saint Louis University Health Sciences Center.*Ms Rogers is a medical student at Saint Louis University School of Medicine. **Dr Gibney was a resident in the Department of Dermatology at Saint Louis University Hospital during the study period and is currently in private practice in Quincy, Mass

      Department of Dermatology, St. Louis University Health Sciences Center, St. Louis, Missouri

      Dermatology, Pediatrics, and

      1998

      Department of Dermatology and Pediatrics, Saint Louis University Health Sciences Center, Missouri, USA.

      Pediatrics, St Louis University Health Sciences Center, St Louis, Missouri.

      1997

      Departments of Pediatrics and Dermatology Saint Louis University Health Sciences Center St. Louis, Missouri, USA

      1996

      Department of Internal Medicine/ Dermatology Division, St. Louis University Medical Center, St. Louis, Missouri, USA, US

      1995

      the Dermatology Associates of Cincinnati, Cincinnati, Ohio, USA

      St. Louis University Health Sciences Center, Division of Dermatology, St. Louis, Missouri

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Elaine C Siegfried is among the top experts in the world.
      Concept World rank
      skinrelated problem #1
      investigational nitric oxide #1
      newborn skin development #1
      confirmed eczema herpeticum #1
      tci data #1
      advance scheduling policy #1
      uncontrolled success rates #1
      label brimonidine #1
      18 nonattendance rate #1
      nonattendance rates #1
      average 6week time #1
      principles infant skin #1
      4 privately #1
      skinthis elaine siegfried #1
      37 nonattendance rate #1
      field pediatric dermatology #1
      binding cassette abca12 #1
      larger study efficacy #1
      longstanding shortage providers #1
      eczema anecdotal reports #1
      treated sb206 #1
      moderatesevere pediatric patients #1
      cutaneous congenital #1
      3 scheduling policies #1
      condyloma children #1
      skin evolving landscape #1
      insurance payment denial #1
      intramural pds #1
      material previous edition #1
      age systemic corticosteroids #1
      stem cellbased mutations #1
      publication brimonidine tartrate #1
      herpeticum response #1
      02timolol #1
      systemic therapy moderatesevere #1
      episode discontinuation #1
      defectsthis chapter material #1
      tci tcs #1
      flares administration #1
      brimonidine 02timolol #1
      pds period #1
      podophyllotoxin recurrence #1
      dupilumab pediatric patients #1
      02timolol 05 #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Elaine C Siegfried

      KOL-Index: 17900

      Importance: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknown in this patient population.

      Objective: To assess the efficacy and safety of dupilumab monotherapy in adolescents with moderate to severe inadequately controlled AD.

      Design, Setting, and ...

      Known for Dupilumab Adolescents | 2 Weeks | Efficacy Safety | Severe Atopic | Quality Life
      KOL-Index: 15057

      BACKGROUND: Children with severe atopic dermatitis (AD) have limited treatment options.

      OBJECTIVE: We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years with severe AD inadequately controlled with topical therapies.

      METHODS: In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1 to 300 mg dupilumab every 4 weeks (300 mg q4w), a weight-based regimen of dupilumab every 2 weeks (100 mg q2w, baseline ...

      Known for Severe Atopic Dermatitis | Dupilumab Tcs | Efficacy Safety | Topical Corticosteroids | 11 Years
      KOL-Index: 13295

      BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis.

      METHODS: In this 48-week study, 211 patients with psoriasis (4 to 17 years of age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram ...

      Known for Plaque Psoriasis | Etanercept Treatment | Placebo Pasi | Children Adolescents | 24 Weeks
      KOL-Index: 13286

      BackgroundAtopic dermatitis is a chronic inflammatory condition with substantial burden and limited treatment options for adolescents with moderate-to-severe disease. Significantly more patients treated with dupilumab vs. placebo achieved Investigator’s Global Assessment 0/1 at week 16.ObjectiveThe objective of this study was to assess the impact of dupilumab treatment vs. placebo on the achievement of clinically meaningful improvements in atopic dermatitis signs, symptoms and quality of ...

      Known for Atopic Dermatitis | Quality Life | Dupilumab Placebo | Signs Symptoms | Clinically Meaningful
      KOL-Index: 11674

      The Comèl-Netherton syndrome is an autosomal recessive multisystemic disorder characterized by localized or generalized congenital ichthyosis, hair shaft abnormalities, immune deficiency, and markedly elevated IgE levels. Life-threatening complications during infancy include temperature and electrolyte imbalance, recurrent infections, and failure to thrive. To study the clinical presentations of the Comèl-Netherton syndrome and its molecular cause, we ascertained 19 unrelated families of ...

      Known for Mutation Detection | Comèlnetherton Syndrome | Ichthyosiform Erythroderma | Preschool Codon | Prenatal Diagnosis
      KOL-Index: 11551

      BACKGROUND: Many clinicians have concerns about the safety of atopic dermatitis (AD) treatments, particularly in children requiring long-term daily maintenance therapy. Topical corticosteroids (TCS) have been widely used for >5 decades. Long-term TCS monotherapy has been associated with adverse cutaneous effects including atrophy, rebound flares, and increased percutaneous absorption with potential for adverse systemic effects. Topical calcineurin inhibitors (TCIs), tacrolimus and ...

      Known for Pediatric Patients | Topical Calcineurin Inhibitors | Atopic Dermatitis | Term Safety | Tcs Tci
      KOL-Index: 11160

      BACKGROUND: There is disparity in access to outpatient care for Medicaid beneficiaries. This inequity disproportionately impacts children. Access for children with skin disease may be especially limited.

      OBJECTIVE: We sought to compare access to dermatologists for new pediatric patients insured by Medicaid versus a private plan.

      METHODS: We surveyed 13 metropolitan markets by conducting secret-shopper scripted telephone calls to dermatology providers listed by Medicaid health plans. ...

      Known for Private Insurance | Access Dermatologists | Health Medicaid | Insured Children | Paired Calls
      KOL-Index: 10469

      Importance: Molluscum contagiosum (MC) is a common viral skin infection that primarily affects children. Cantharidin, a topical vesicant, has a long history of use for MC in compounded formulations, but the safety and efficacy of doses, regimens, and application methods have not been demonstrated in large-scale trials.

      Objective: To determine the safety and efficacy of VP-102, a drug-device combination containing cantharidin, 0.7% (w/v), compared with vehicle in individuals with ...

      Known for Vp102 Vehicle | Complete Clearance | Molluscum Contagiosum | Cantharidin 07 | Device Combination
      KOL-Index: 8727

      Importance: Dupilumab subcutaneous injection is approved for treating moderate-to-severe atopic dermatitis (AD) in adolescents, but there has been too little research on an efficacious systemic oral treatment with a favorable benefit-risk profile for adolescents with moderate-to-severe AD.

      Objective: To investigate the efficacy and safety of oral abrocitinib plus topical therapy in adolescents with moderate-to-severe AD.

      Design, Setting, and Participants: The phase 3, randomized, ...

      Known for Adolescents Moderatetosevere | Oral Abrocitinib | Atopic Dermatitis | Topical Therapy | Placebo 12 Weeks
      KOL-Index: 8638

      OBJECTIVE: To assess early intervention with pimecrolimus combined with corticosteroid (CS) for major flares in patients with severe atopic dermatitis (AD).

      METHODS: In this 6-month, double-blind, multicenter, randomized, vehicle-controlled, parallel-group in 35 US centers, 275 children aged 3 months to 11 years with mild to severe AD applied the study medication twice daily at first signs/symptoms of AD. For major flares not controlled with study medication, a mid-potency CS cream ...

      Known for Pimecrolimus Cream | Preschool Dermatitis | Study Medication | Outcome Measure | Calcineurin Inhibitors
      KOL-Index: 8614

      BackgroundConjunctivitis is a known comorbidity of atopic dermatitis. Dupilumab clinical trials for moderate-to-severe atopic dermatitis in adults showed a higher conjunctivitis incidence for dupilumab-treated patients than placebo-treated patients, whereas trials for uncontrolled asthma reported lower rates for both dupilumab and placebo.ObjectiveThe objective of this study was to evaluate the incidence and severity of conjunctivitis in dupilumab clinical trials in adolescents with ...

      Known for Atopic Dermatitis | Dupilumab Placebo | Adolescents Moderate | Humanized Asthma | Lower Rates
      KOL-Index: 8497

      Therapeutic options for superficial infantile hemangiomas (IH) are limited. Recently, timolol maleate gel, a topical nonselective beta-blocker, has been reported as a potentially effective treatment for superficial IH. This study is an extension of a previously published pilot study designed to further investigate the efficacy and safety and to identify predictors of good response of topical 0.5% or 0.1% timolol maleate gel-forming solution. This was a retrospective cohort study ...

      Known for Timolol Maleate | Infantile Hemangiomas | Patients Superficial | Forming Solution | Study Efficacy
      KOL-Index: 8487

      BACKGROUND: No systemic therapies are approved by the US Food and Drug Administration for the treatment of psoriasis in children and adolescents.

      OBJECTIVE: We sought to evaluate the long-term safety and efficacy of etanercept in pediatric patients (aged 4-17 years) with moderate to severe plaque psoriasis.

      METHODS: Patients who completed or received substantial treatment benefit in a 48-week, randomized, double-blind, placebo-controlled study (N = 211) evaluating the efficacy and safety ...

      Known for Pediatric Patients | Plaque Psoriasis | Efficacy Etanercept | Topic Receptors | Systemic Therapies
      KOL-Index: 8024

      Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥2 yr old) and adults with ...

      Known for Atopic Dermatitis | Boxed Warning | Topical Corticosteroids | Anti Inflammatory | Term Safety
      KOL-Index: 8023

      Importance: Use of systemic therapies for moderate to severe psoriasis in children is increasing, but comparative data on their use and toxicities are limited.

      Objective: To assess patterns of use and relative risks of systemic agents for moderate to severe psoriasis in children.

      Design, Setting, and Participants: A retrospective review was conducted at 20 centers in North America and Europe, and included all consecutive children with moderate to severe psoriasis who used systemic ...

      Known for Pediatric Psoriasis | Systemic Agents | Methotrexate Week | Folic Acid | Necrosis Factor

      Key People For Atopic Dermatitis

      Top KOLs in the world
      #1
      Donald Y M Leung
      atopic dermatitis eczema herpeticum food allergy
      #2
      Thomas RM Bieber
      atopic dermatitis dendritic cells lupus erythematosus
      #3
      Jon M Hanifin
      atopic dermatitis eczema herpeticum histamine release
      #4
      Mark Boguniewicz
      atopic dermatitis eczema herpeticum tacrolimus ointment
      #5
      Hywel C G Williams
      atopic eczema cochrane skin basal cell carcinoma
      #6
      Johnannes Ring
      atopic eczema west germany histamine release

      Departments of Pediatrics and Dermatology, Saint Louis University School of Medicine, St. Louis, Missouri, USA | Division of Dermatology, Department of Pediatrics, Cardinal Glennon Children's Hospital, St. Louis University School of Medicine, 1465 So

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.